119-433: Tacrolimus , sold under the brand name Prograf among others, is an immunosuppressive drug . After allogenic organ transplant , the risk of organ rejection is moderate. To lower the risk of organ rejection, tacrolimus is given. The drug can also be sold as a topical medication in the treatment of T cell-mediated diseases such as eczema and psoriasis . For example, it is prescribed for severe refractory uveitis after
238-540: A body mass index in excess of 30 kg/m (classified as obese). Sirolimus is metabolized by the CYP3A4 enzyme and is a substrate of the P-glycoprotein (P-gp) efflux pump ; hence, inhibitors of either protein may increase sirolimus concentrations in blood plasma , whereas inducers of CYP3A4 and P-gp may decrease sirolimus concentrations in blood plasma. Unlike the similarly named tacrolimus , sirolimus
357-417: A bone marrow transplant, exacerbations of minimal change disease , Kimura's disease , and vitiligo . It can be used to treat dry eye syndrome in cats and dogs. Tacrolimus inhibits calcineurin , which is involved in the production of interleukin-2 , a molecule that promotes the development and proliferation of T cells , as part of the body's learned (or adaptive ) immune response. Chemically, it
476-467: A calcineurin inhibitor (such as tacrolimus ), and/or mycophenolate mofetil , to provide steroid-free immunosuppression regimens. Impaired wound healing and thrombocytopenia are possible side effects of sirolimus; therefore, some transplant centers prefer not to use it immediately after the transplant operation, but instead administer it only after a period of weeks or months. Its optimal role in immunosuppression has not yet been determined, and it remains
595-457: A folic acid analogue. It binds dihydrofolate reductase and prevents synthesis of tetrahydrofolate . It is used in the treatment of autoimmune diseases (for example rheumatoid arthritis or Behcet's Disease) and in transplantations. Azathioprine (Prometheus' Imuran), is the main immunosuppressive cytotoxic substance. It is extensively used to control transplant rejection reactions. It is nonenzymatically cleaved to mercaptopurine , that acts as
714-570: A blood sample before the next dose, which gives the trough level. However, good correlation is noted between trough concentration levels and drug exposure, known as area under the concentration-time curve, for both sirolimus (SRL) and tacrolimus (TAC) (SRL: r2 = 0.83; TAC: r2 = 0.82), so only one level need be taken to know its pharmacokinetic (PK) profile. PK profiles of SRL and of TAC are unaltered by simultaneous administration. Dose-corrected drug exposure of TAC correlates with SRL (r2 = 0.8), so patients have similar bioavailability of both. Sirolimus
833-574: A clinical trial conducted by Wyeth showed an increased mortality in stable liver transplant patients after switching from a calcineurin inhibitor-based immunosuppressive regimen to sirolimus. A 2019 cohort study of nearly 10,000 lung transplant recipients in the US demonstrated significantly improved long-term survival using sirolimus + tacrolimus instead of mycophenolate mofetil + tacrolimus for immunosuppressive therapy starting at one year after transplant. Sirolimus can also be used alone, or in conjunction with
952-505: A distinct MTase, at C27 to yield rapamycin. The biosynthetic genes responsible for rapamycin synthesis have been identified. As expected, three extremely large open reading frames (ORF's) designated as rapA , rapB , and rapC encode for three extremely large and complex multienzymes, RapA, RapB, and RapC, respectively. The gene rapL has been established to code for a NAD+ -dependent lysine cycloamidase, which converts L- lysine to L- pipecolic acid (figure 4) for incorporation at
1071-598: A life-threatening reaction of the cardiovascular system and the central nervous system, requiring a lengthy therapy. Past this period CD3 blocks the TCR-antigen binding and causes conformational change or the removal of the entire TCR3/CD3 complex from the T-cell surface. This lowers the number of available T-cells, perhaps by sensitizing them for the uptake by the epithelial reticular cells . The cross-binding of CD3 molecules as well activates an intracellular signal causing
1190-684: A low vaccination rate against some Vaccine-preventable disease among patients taking immunosuppressive drugs, despite a generally positive attitude towards vaccinations. There are also other side-effects, such as hypertension , dyslipidemia , hyperglycemia , peptic ulcers , lipodystrophy , moon face , liver and kidney injury . The immunosuppressive drugs also interact with other medicines and affect their metabolism and action. Actual or suspected immunosuppressive agents can be evaluated in terms of their effects on lymphocyte subpopulations in tissues using immunohistochemistry . Sirolimus Sirolimus , also known as rapamycin and sold under
1309-460: A manner similar to tacrolimus. Unlike the tacrolimus-FKBP12 complex, which inhibits calcineurin (PP2B), the sirolimus-FKBP12 complex inhibits the mTOR (mammalian Target Of Rapamycin, rapamycin being another name for sirolimus) pathway by directly binding to mTOR Complex 1 (mTORC1). mTOR has also been called FRAP (FKBP-rapamycin-associated protein), RAFT (rapamycin and FKBP target), RAPT1, or SEP. The earlier names FRAP and RAFT were coined to reflect
SECTION 10
#17327803313651428-593: A new medical treatment option for both vascular tumors and vascular malformations, as a mammalian target of rapamycin (mTOR), capable of integrating signals from the PI3K/AKT pathway to coordinate proper cell growth and proliferation. Hence, sirolimus is ideal for "proliferative" vascular tumors through the control of tissue overgrowth disorders caused by inappropriate activation of the PI3K/AKT/mTOR pathway as an antiproliferative agent. Sirolimus has been used as
1547-437: A non-competitive, selective, and reversible inhibitor of inosine-5′-monophosphate dehydrogenase (IMPDH), which is a key enzyme in the de novo guanosine nucleotide synthesis. In contrast to other human cell types, lymphocytes B and T are very dependent on this process. Mycophenolate mofetil is used in combination with ciclosporin or tacrolimus in transplant patients. Fingolimod is a synthetic immunosuppressant. It increases
1666-422: A post-transplant cocktail including steroids , mycophenolate , and IL-2 receptor inhibitors such as basiliximab . Dosages are titrated to target blood levels at specific times after medication administration. As an ointment , tacrolimus is used in the treatment of dermatitis (eczema), in particular atopic dermatitis , if topical corticosteroids and moisturisers fail in helping. It suppresses inflammation in
1785-551: A purine analogue and an inhibitor of DNA synthesis. Mercaptopurine itself can also be administered directly. By preventing the clonal expansion of lymphocytes in the induction phase of the immune response, it affects both the cell and the humoral immunity . It is also efficient in the treatment of autoimmune diseases. Among these, dactinomycin is the most important. It is used in kidney transplantations . Other cytotoxic antibiotics are anthracyclines , mitomycin C , bleomycin , mithramycin . Antibodies are sometimes used as
1904-462: A quick and potent immunosuppressive therapy to prevent the acute rejection reactions as well as a targeted treatment of lymphoproliferative or autoimmune disorders (e.g., anti- CD20 monoclonals). Heterologous polyclonal antibodies are obtained from the serum of animals (e.g., rabbit , horse ), and injected with the patient's thymocytes or lymphocytes. The antilymphocyte ( ALG ) and antithymocyte antigens ( ATG ) are being used. They are part of
2023-430: A related compound, everolimus , increased elderly patients' immune response on an intermittent dose. This led to many in the anti-aging community self-experimenting with the compound. However, because of the different biochemical properties of sirolimus, the dosing is potentially very different from that of everolimus. Ultimately, due to known side-effects of sirolimus, as well as inadequate evidence for optimal dosing, it
2142-506: A sex-specific manner: limited rapamycin exposure enhanced male but not female lifespan, providing evidence for sex differences in sirolimus response. The results are further supported by the finding that genetically modified mice with impaired mTORC1 signalling live longer. Sirolimus has potential for widespread use as a longevity-promoting drug, with evidence pointing to its ability to prevent age-associated decline of cognitive and physical health. In 2014, researchers at Novartis showed that
2261-563: A similar way to steroids , and is equally as effective as a mid-potency steroid. An important advantage of tacrolimus is that, unlike steroids, it does not cause skin thinning ( atrophy ), or other steroid related side effects. It is applied on the active lesions until they heal off, but may also be used continuously in low doses (twice a week), and applied to the thinner skin over the face and eyelids. Clinical trials of up to one year have been conducted. Recently it has also been used to treat segmental vitiligo in children, especially in areas on
2380-456: A starter unit, four molecules of malonyl-CoA, five molecules of methylmalonyl-CoA, one molecule of allylmalonyl-CoA as elongation units. However, two molecules of malonyl-CoA are able to be replaced by two molecules of methoxymalonyl CoA. Once two malonyl-CoA molecules are replaced, post-synthase tailoring steps are no longer required where two methoxymalonyl CoA molecules are substituted. The biosynthesis of methoxymalonyl CoA to Acyl Carrier protein
2499-408: A topical treatment of angiofibromas with tuberous sclerosis complex (TSC). Facial angiofibromas occur in 80% of patients with TSC, and the condition is very disfiguring. A retrospective review of English-language medical publications reporting on topical sirolimus treatment of facial angiofibromas found sixteen separate studies with positive patient outcomes after using the drug. The reports involved
SECTION 20
#17327803313652618-434: A total of 84 patients, and improvement was observed in 94% of subjects, especially if treatment began during the early stages of the disease. Sirolimus treatment was applied in several different formulations (ointment, gel, solution, and cream), ranging from 0.003 to 1% concentrations. Reported adverse effects included one case of perioral dermatitis, one case of cephalea, and four cases of irritation. In April 2022, sirolimus
2737-452: A treatment for severe acute respiratory syndrome coronavirus 2 insofar as its immunosuppressive effects could prevent or reduce the cytokine storm seen in very serious cases of COVID-19. Moreover, inhibition of cell proliferation by rapamycin could reduce viral replication . Rapamycin can accelerate degradation of oxidized LDL cholesterol in endothelial cells , thereby lowering the risk of atherosclerosis. Oxidized LDL cholesterol
2856-550: Is immunodeficiency , because the majority of them act non-selectively, resulting in increased susceptibility to infections , decreased cancer immunosurveillance and decreased ability to produce antibodies after vaccination . However, the vaccination status of patients taking immunosuppressive drugs for chronic diseases such as Rheumatoid arthritis or Inflammatory bowel disease should be investigated before starting any treatment, and patients should eventually be vaccinated against Vaccine-preventable disease . Some studies showed
2975-461: Is a calcineurin inhibitor (CNI). It has been in use since 1983 and is one of the most widely used immunosuppressive drugs. It is a cyclic fungal peptide, composed of 11 amino acids. Ciclosporin is thought to bind to the cytosolic protein cyclophilin (an immunophilin ) of immunocompetent lymphocytes, especially T-lymphocytes . This complex of ciclosporin and cyclophilin inhibits the phosphatase calcineurin , which under normal circumstances induces
3094-583: Is a macrolide lactone that was first discovered in 1987, from the fermentation broth of a Japanese soil sample that contained the bacterium Streptomyces tsukubensis . It is on the World Health Organization's List of Essential Medicines . In 2021, it was the 296th most commonly prescribed medication in the United States, with more than 500,000 prescriptions. It has similar immunosuppressive properties to ciclosporin , but
3213-458: Is a natural product and macrocyclic lactone . The biosynthesis of the rapamycin core is accomplished by a type I polyketide synthase (PKS) in conjunction with a nonribosomal peptide synthetase (NRPS). The domains responsible for the biosynthesis of the linear polyketide of rapamycin are organized into three multienzymes, RapA, RapB, and RapC, which contain a total of 14 modules (figure 1). The three multienzymes are organized such that
3332-415: Is a lack of consistent evidence as to whether dosing based on rs776746 genotype results in improved clinical outcomes (such as a decreased risk for transplant rejection or drug toxicities), likely because patients taking tacrolimus are subject to therapeutic drug monitoring . Studies have shown that genetic polymorphisms of genes other than CYP3A5, such as NR1I2 (encoding PXR ), also significantly influence
3451-408: Is a major contributor to atherosclerosis. As of 2016, studies in cells, animals, and humans have suggested that mTOR activation as process underlying systemic lupus erythematosus and that inhibiting mTOR with rapamycin may be a disease-modifying treatment. As of 2016 rapamycin had been tested in small clinical trials in people with lupus. Lymphatic malformation , lymphangioma or cystic hygroma,
3570-499: Is a product of the bacterium Streptomyces tsukubensis . It is a macrolide lactone and acts by inhibiting calcineurin . The drug is used primarily in liver and kidney transplantations, although in some clinics it is used in heart, lung, and heart/lung transplantations. It binds to the immunophilin FKBP1A , followed by the binding of the complex to calcineurin and the inhibition of its phosphatase activity. In this way, it prevents
3689-434: Is a serious complication associated with sirolimus therapy, especially in the case of lung transplants. The mechanism of the interstitial pneumonitis caused by sirolimus and other macrolide MTOR inhibitors is unclear, and may have nothing to do with the mTOR pathway. The interstitial pneumonitis is not dose-dependent, but is more common in patients with underlying lung disease. There have been warnings about
Tacrolimus - Misplaced Pages Continue
3808-417: Is also metabolized primarily by the CYP3A4 enzyme. The bioavailabiliy of sirolimus is low, and the absorption of sirolimus into the blood stream from the intestine varies widely between patients, with some patients having up to eight times more exposure than others for the same dose. Drug levels are, therefore, taken to make sure patients get the right dose for their condition. This is determined by taking
3927-412: Is an abnormal growth of lymphatic vessels that usually affects children around the head and neck area and more rarely involving the tongue causing macroglossia. LM is caused by a PIK3CA mutation during lymphangiogenesis early in gestational cell formation causing the malformation of lymphatic tissue. Treatment often consists of removal of the affected tissue via excision, laser ablation or sclerotherapy, but
4046-557: Is common and can result in significant morbidity and mortality. The results of several studies suggest that calcineurin inhibitors have oncogenic properties mainly linked to the production of cytokines that promote tumor growth, metastasis and angiogenesis. This drug has been reported to reduce the frequency of regulatory T cells (T-Reg) and after converting from a CNI monotherapy to a mycophenolate monotherapy, patients were found to have increased graft success and T-Reg frequency. Tacrolimus (trade names Prograf, Astagraf XL, Envarsus XR)
4165-475: Is decreased production of IL-2. This further decreases the proliferation of T cells. Glucocorticoids also suppress the humoral immunity , causing B cells to express smaller amounts of IL-2 and IL-2 receptors . This diminishes both B cell clone expansion and antibody synthesis. Glucocorticoids influence all types of inflammatory events, no matter their cause. They induce the lipocortin-1 (annexin-1) synthesis, which then binds to cell membranes preventing
4284-419: Is derived from the shikimate pathway . Note that the cyclohexane ring of the starting unit is reduced during the transfer to module 1. The starting unit is then modified by a series of Claisen condensations with malonyl or methylmalonyl substrates, which are attached to an acyl carrier protein (ACP) and extend the polyketide by two carbons each. After each successive condensation , the growing polyketide
4403-411: Is expressed only by the already-activated T lymphocytes. Therefore, it is of special significance to the selective immunosuppressive treatment, and research has been focused on the development of effective and safe anti-IL-2 antibodies. By the use of recombinant gene technology , the mouse anti-Tac antibodies have been modified, leading to the presentation of two chimeric mouse/human anti-Tac antibodies in
4522-428: Is formulated in a polymer coating that affords controlled release through the healing period following coronary intervention. Several large clinical studies have demonstrated lower restenosis rates in patients treated with sirolimus-eluting stents when compared to bare-metal stents, resulting in fewer repeat procedures. A sirolimus-eluting coronary stent was marketed by Cordis , a division of Johnson & Johnson , under
4641-479: Is further modified according to enzymatic domains that are present to reduce and dehydrate it, thereby introducing the diversity of functionalities observed in rapamycin (figure 1). Once the linear polyketide is complete, L-pipecolic acid, which is synthesized by a lysine cycloamidase from an L-lysine, is added to the terminal end of the polyketide by an NRPS. Then, the NSPS cyclizes the polyketide, giving prerapamycin,
4760-430: Is however needed to develop and create targeted, effective treatment therapies for LM. Due to its immunosuppressant activity, Rapamycin has been assessed as prophylaxis or treatment agent of Graft-versus-host disease (GVHD), a complication of hematopoietic stem cell transplantation . While contrasted results were obtained in clinical trials, pre-clinical studies have shown that Rapamycin can mitigate GVHD by increasing
4879-535: Is indicated for the prophylaxis of organ rejection in adults at low to moderate immunological risk receiving a renal transplant and, as Hyftor, is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex. The chief advantage sirolimus has over calcineurin inhibitors is its low toxicity toward kidneys. Transplant patients maintained on calcineurin inhibitors long-term tend to develop impaired kidney function or even kidney failure ; this can be avoided by using sirolimus instead. It
Tacrolimus - Misplaced Pages Continue
4998-421: Is metabolized by the CYP3A4 enzyme and is a substrate of the P-glycoprotein (P-gp) efflux pump . It has linear pharmacokinetics. In studies on N=6 and N=36 subjects, peak concentration was obtained in 1.3 hours +/r- 0.5 hours and the terminal elimination was slow, with a half life around 60 hours +/- 10 hours. Sirolimus was not found to effect the concentration of ciclosporin , which
5117-419: Is much more potent. Immunosuppression with tacrolimus was associated with a significantly lower rate of acute rejection compared with ciclosporin-based immunosuppression (30.7% vs 46.4%) in one study. Clinical outcome is better with tacrolimus than with ciclosporin during the first year of liver transplantation. Long-term outcome has not been improved to the same extent. Tacrolimus is normally prescribed as part of
5236-514: Is not a calcineurin inhibitor , but it has a similar suppressive effect on the immune system. Sirolimus inhibits IL-2 and other cytokine receptor-dependent signal transduction mechanisms, via action on mTOR , and thereby blocks activation of T and B cells . Ciclosporin and tacrolimus inhibit the secretion of IL-2, by inhibiting calcineurin . The mode of action of sirolimus is to bind the cytosolic protein FK-binding protein 12 (FKBP12) in
5355-461: Is particularly advantageous in patients with kidney transplants for hemolytic-uremic syndrome , as this disease is likely to recur in the transplanted kidney if a calcineurin-inhibitor is used. However, on 7 October 2008, the FDA approved safety labeling revisions for sirolimus to warn of the risk for decreased renal function associated with its use. In 2009, the FDA notified healthcare professionals that
5474-602: Is possible to diminish their toxicity by using highly purified serum fractions and intravenous administration in the combination with other immunosuppressants, for example, calcineurin inhibitors , cytostatics, and corticosteroids . The most frequent combination is to use antibodies and ciclosporin simultaneously in order to prevent patients from gradually developing a strong immune response to these drugs, reducing or eliminating their effectiveness. Monoclonal antibodies are directed towards exactly defined antigens. Therefore, they cause fewer side-effects. Especially significant are
5593-540: Is predominantly eliminated via the faeces in form of its metabolites. When applied locally on eczema, tacrolimus has little to no bioavailability. The predominant enzyme responsible for metabolism of tacrolimus is CYP3A5 . Genetic variations within CYP3A5 that result in changes to the activity of the CYP3A5 protein can affect concentrations of tacrolimus within the body. In particular, individuals who are homozygous for
5712-399: Is probably the most potent immunosuppressive compound. In small doses, it is very efficient in the therapy of systemic lupus erythematosus , autoimmune hemolytic anemias , granulomatosis with polyangiitis , and other immune diseases. High doses cause pancytopenia and hemorrhagic cystitis . Antimetabolites interfere with the synthesis of nucleic acids. These include: Methotrexate is
5831-424: Is proceeded by five enzymes (fkbG, fkbH, fkbI, fkbJ, and fkbK). Allylmalonyl-CoA is also able to be replaced by propionylmalonyl-CoA. The starter unit, DHCHC from the chorismic acid is formed by fkbO enzyme and loaded onto CoA-ligase domain (CoL). Then, it proceeds to NADPH dependent reduction(ER). Three enzymes, fkbA,B,C enforce processes from the loading module to the module 10, the last step of PKS 1. fkbB enzyme
5950-435: Is provided in a hospital, where adequate isolation from infection is available. They are usually administered for five days intravenously in the appropriate quantity. Patients stay in the hospital as long as three weeks to give the immune system time to recover to a point where there is no longer a risk of serum sickness . Because of a high immunogenicity of polyclonal antibodies, almost all patients have an acute reaction to
6069-514: Is responsible of C9 (depicted in green). After these tailoring steps, the tacrolimus molecule becomes biologically active. Tacrolimus has been shown to reduce the risk of serious infections while also increasing remission of kidney function in lupus nephritis . Tacrolimus has been used to suppress the inflammation associated with ulcerative colitis (UC), a form of inflammatory bowel disease . Although almost exclusively used in trial cases only, tacrolimus has shown to be significantly effective in
SECTION 50
#17327803313656188-484: Is responsible of allylmalonyl-CoA synthesis or possibly propionylmalonyl-CoA at C21, which it is an unusual step of general PKS 1. As mentioned, if two methoxymalonyl CoA molecules are substituted for two malonyl-CoA molecules, they will take place in module 7 and 8 (C13 and C15), and fkbA enzyme will enforce this process. After the last step (module 10) of PKS 1, one molecule of L - pipecolic acid formed from L - lysine and catalyzed through fkbL enzyme synthesizes with
6307-426: Is similar to that of cyclosporin, the incidence of acute rejection is reduced by tacrolimus use over cyclosporin use. Although short-term immunosuppression concerning patient and graft survival is found to be similar between the two drugs, tacrolimus results in a more favorable lipid profile, and this may have important long-term implications given the prognostic influence of rejection on graft survival. Oral tacrolimus
6426-416: Is slowly absorbed in the gastrointestinal tract , with a total bioavailability of 20 to 25% (but with variations from 5 to 67%) and highest blood plasma concentrations (C max ) reached after one to three hours. Taking the drug together with a meal, especially one rich in fat, slows down resorption and reduces bioavailability. In the blood, tacrolimus is mainly bound to erythrocytes ; only 5% are found in
6545-465: Is still a subject of controversy. The FDA issued a health warning in March 2005 for the drug, based on animal models and a small number of patients. Until further human studies yield more conclusive results, the FDA recommends that users be advised of the potential risks. However, current practice by UK dermatologists is not to consider this a significant real concern and they are increasingly recommending
6664-463: Is then modified (figure 3) by an additional five enzymes, which lead to the final product, rapamycin. First, the core macrocycle is modified by RapI, SAM-dependent O-methyltransferase (MTase), which O-methylates at C39. Next, a carbonyl is installed at C9 by RapJ, a cytochrome P-450 monooxygenases (P-450). Then, RapM, another MTase, O-methylates at C16. Finally, RapN, another P-450, installs a hydroxyl at C27 immediately followed by O-methylation by Rap Q,
6783-504: The IL-2 receptor - (CD25-) and CD3-directed antibodies. They are used to prevent the rejection of transplanted organs, but also to track changes in the lymphocyte subpopulations. It is reasonable to expect similar new drugs in the future. Muromonab-CD3 is a murine anti-CD3 monoclonal antibody of the IgG2a type that was previously used to prevent T-cell activation and proliferation by binding
6902-533: The acute transplant rejection and graft-versus-host disease . Nevertheless, they do not prevent an infection and also inhibit later reparative processes . Glucocorticoids suppress cell-mediated immunity . They act by inhibiting gene expression of cytokines including Interleukin 1 (IL-1), IL-2 , IL-3 , IL-4 , IL-5 , IL-6 , IL-8 , and TNF-alpha by binding to corticosteroid response elements on DNA. This decrease in cytokine production reduces T cell proliferation. With decreased T cell proliferation there
7021-713: The circulation in the spleen and liver . In this way, polyclonal antibodies inhibit cell-mediated immune reactions, including graft rejection, delayed hypersensitivity (i.e., tuberculin skin reaction), and the graft-versus-host disease (GVHD), but influence thymus -dependent antibody production. As of March 2005, there are two preparations available to the market: Atgam , obtained from horse serum, and Thymoglobuline , obtained from rabbit serum. Polyclonal antibodies affect all lymphocytes and cause general immunosuppression, possibly leading to post-transplant lymphoproliferative disorders (PTLD) or serious infections, especially by cytomegalovirus . To reduce these risks, treatment
7140-477: The cytotoxic effects of chemotherapy drugs, such as doxorubicin or cyclophosphamide . Sirolimus blocks Akt signalling and the cells lose their resistance to the chemotherapy. Bcl-2 -positive lymphomas were completely resistant to the therapy; eIF4E -expressing lymphomas are not sensitive to sirolimus. Sirolimus also shows promise in treating tuberous sclerosis complex (TSC), a congenital disorder that predisposes those afflicted to benign tumor growth in
7259-794: The mTOR signaling pathway, resulting in the release of lymphangiogenic growth factors . Sirolimus blocks this pathway. The safety and efficacy of sirolimus treatment of LAM were investigated in clinical trials that compared sirolimus treatment with a placebo group in 89 patients for 12 months. The patients were observed for 12 months after the treatment had ended. The most commonly reported side effects of sirolimus treatment of LAM were mouth and lip ulcers, diarrhea , abdominal pain, nausea, sore throat, acne, chest pain, leg swelling, upper respiratory tract infection , headache, dizziness, muscle pain and elevated cholesterol . Serious side effects including hypersensitivity and swelling ( edema ) have been observed in renal transplant patients. While sirolimus
SECTION 60
#17327803313657378-514: The phospholipase A2 from coming into contact with its substrate arachidonic acid . This leads to diminished eicosanoid production. The cyclooxygenase (both COX-1 and COX-2) expression is also suppressed, potentiating the effect. Glucocorticoids also stimulate the lipocortin-1 escaping to the extracellular space, where it binds to the leukocyte membrane receptors and inhibits various inflammatory events: epithelial adhesion , emigration , chemotaxis , phagocytosis , respiratory burst , and
7497-454: The plasma , of which more than 98.8% are bound to plasma proteins . The substance is metabolized in the liver, mainly via CYP3A , and in the intestinal wall. All metabolites found in the circulation are inactive. Biological half-life varies widely and seems to be higher for healthy persons (43 hours on average) than for patients with liver transplants (12 hours) or kidney transplants (16 hours), due to differences in clearance . Tacrolimus
7616-573: The European Union in May 2023. Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of lymphangioleiomyomatosis (LAM). Sirolimus (Fyarro), as protein-bound particles, is indicated for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). In the EU, sirolimus, as Rapamune,
7735-474: The G allele at the single nucleotide polymorphism (SNP) rs776746 (also known as CYP3A5 *3/*3) have a non-functional CYP3A5 protein. The frequency of the G allele varies worldwide, from 4% in some African populations to 80–90% in Caucasian populations. Across a large number of studies, individuals homozygous for the G allele have been shown to have higher concentrations of tacrolimus and require lower doses of
7854-437: The T cell anergy or apoptosis, unless the cells receive another signal through a co-stimulatory molecule . CD3 antibodies shift the balance from Th1 to Th2 cells as CD3 stimulates Th1 activation. The patient may develop neutralizing antibodies reducing the effectiveness of muromonab-CD3. Muromonab-CD3 can cause excessive immunosuppression. Although CD3 antibodies act more specifically than polyclonal antibodies, they lower
7973-458: The T-cell receptor complex present on all differentiated T cells. As such it was one of the first potent immunosuppressive substances and was administered to control the steroid- and/or polyclonal antibodies-resistant acute rejection episodes. As it acts more specifically than polyclonal antibodies it was also used prophylactically in transplantations. However, muromonab-CD3 is no longer produced, and this mouse monoclonal antibody has been replaced in
8092-570: The United States. mTOR , specifically mTORC1, was first shown to be important in aging in 2003, in a study on worms; sirolimus was shown to inhibit and slow aging in worms, yeast, and flies, and then to improve the condition of mouse models of various diseases of aging. Sirolimus was first shown to extend lifespan in wild-type mice in a study published by NIH investigators in 2009; the studies have been replicated in mice of many different genetic backgrounds. A study published in 2020 found late-life sirolimus dosing schedules enhanced mouse lifespan in
8211-433: The azole class ( fluconazole , voriconazole ), increase tacrolimus levels by competing for cytochrome enzymes. Tacrolimus is a macrolide calcineurin inhibitor . In T cells , activation of the T cell receptor normally increases intracellular calcium, which acts via calmodulin to activate calcineurin . Calcineurin then dephosphorylates the transcription factor nuclear factor of activated T cells (NF-AT), which moves to
8330-523: The brain, heart, kidneys, skin, and other organs. After several studies conclusively linked mTOR inhibitors to remission in TSC tumors, specifically subependymal giant-cell astrocytomas in children and angiomyolipomas in adults, many US doctors began prescribing sirolimus (Wyeth's Rapamune) and everolimus (Novartis's RAD001) to TSC patients off-label. Numerous clinical trials using both rapamycin analogs, involving both children and adults with TSC, are underway in
8449-470: The brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents , prevent organ transplant rejection , treat a rare lung disease called lymphangioleiomyomatosis , and treat perivascular epithelioid cell tumour (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mammalian target of rapamycin (mTOR) kinase inhibitor that reduces
8568-723: The cancer risk in some transplant patients. Sirolimus was shown to inhibit the progression of dermal Kaposi's sarcoma in patients with renal transplants. Other mTOR inhibitors , such as temsirolimus (CCI-779) or everolimus (RAD001), are being tested for use in cancers such as glioblastoma multiforme and mantle cell lymphoma . However, these drugs have a higher rate of fatal adverse events in cancer patients than control drugs. A combination therapy of doxorubicin and sirolimus has been shown to drive Akt -positive lymphomas into remission in mice. Akt signalling promotes cell survival in Akt-positive lymphomas and acts to prevent
8687-399: The cell cycle. In a similar manner, Sirolimus prevents B cell differentiation into plasma cells, reducing production of IgM, IgG, and IgA antibodies. It is also active against tumors that are PI3K/AKT/mTOR-dependent. Everolimus is an analog of sirolimus and also is an mTOR inhibitor. Zotarolimus is a semi-synthetic derivative of sirolimus used in drug-eluting stents . IFN-β suppresses
8806-521: The cell from transitioning from the G 0 into G 1 phase of the cell cycle . Tacrolimus is more potent than ciclosporin and has less pronounced side-effects. Sirolimus (rapamycin, trade name Rapamune) is a macrolide lactone, produced by the actinomycete bacterium Streptomyces hygroscopicus . It is used to prevent rejection reactions. Although it is a structural analogue of tacrolimus, it acts somewhat differently and has different side-effects. Contrary to ciclosporin and tacrolimus, drugs that affect
8925-405: The cell-mediated immunity significantly, predisposing the patient to opportunistic infections and malignancies. Interleukin-2 is an important immune system regulator necessary for the clone expansion and survival of activated lymphocytes T. Its effects are mediated by the trimer cell surface receptor IL-2a , consisting of the α, β, and γ chains. The IL-2a (CD25, T-cell activation antigen, TAC)
9044-428: The clinic with chimeric, humanized, or human monoclonal antibodies. The muromonab's mechanism of action is only partially understood. It is known that the molecule binds TCR/CD3 receptor complex. In the first few administrations this binding non-specifically activates T-cells, leading to a serious syndrome 30 to 60 minutes later. It is characterized by fever, myalgia , headache, and arthralgia . Sometimes it develops in
9163-401: The drug's benefits, it also inhibits mTORC2 , which results in diabetes-like symptoms. This includes decreased glucose tolerance and insensitivity to insulin. Sirolimus treatment may additionally increase the risk of type 2 diabetes. In mouse studies, these symptoms can be avoided through the use of alternate dosing regimens or analogs such as everolimus or temsirolimus . Lung toxicity
9282-443: The drug, as compared to individuals who are not homozygous for the G allele. Achieving target concentrations of tacrolimus is important – if levels are too low, then there is a risk of transplant rejection , if levels are too high, there is a risk of drug toxicities. There is evidence to suggest that dosing patients based on rs776746 genotype can result in faster and more frequent achievement of target tacrolimus levels. However, there
9401-455: The end of the polyketide. The gene rapP , which is embedded between the PKS genes and translationally coupled to rapC , encodes for an additional enzyme , an NPRS responsible for incorporating L-pipecolic acid, chain termination and cyclization of prerapamycin. In addition, genes rapI , rapJ , rapM , rapN , rapO , and rapQ have been identified as coding for tailoring enzymes that modify
9520-498: The expression or changes the function of certain adhesion molecules (α4/β7 integrin ) in lymphocytes, so they accumulate in the lymphatic tissue (lymphatic nodes) and their number in the circulation is diminished. In this respect, it differs from all other known immunosuppressants. Myriocin has been reported being 10 to 100 times more potent than Ciclosporin . Immunosuppressive drugs are used in immunosuppressive therapy to: A common side-effect of many immunosuppressive drugs
9639-865: The face. Tacrolimus solution, as drops, is sometimes prescribed by veterinarians for keratoconjunctivitis , and other dry eye maladies, in the eyes of domestic cats , dogs , and horses . It has been studied for use in human eyes. Contraindications and precautions include: Side effects can be severe and include infection , cardiac damage, hypertension , blurred vision , liver and kidney problems (tacrolimus nephrotoxicity ), hyperkalemia , hypomagnesemia , hyperglycemia , diabetes mellitus , itching , lung damage ( sirolimus also causes lung damage), and various neuropsychiatric problems such as loss of appetite, insomnia , posterior reversible encephalopathy syndrome , confusion, weakness, depression , vivid nightmares, cramps , neuropathy , seizures , tremors , and catatonia . In addition, it may potentially increase
9758-522: The fact that sirolimus must bind FKBP12 first, and only the FKBP12-sirolimus complex can bind mTOR. However, mTOR is now the widely accepted name, since Tor was first discovered via genetic and molecular studies of sirolimus-resistant mutants of Saccharomyces cerevisiae that identified FKBP12, Tor1, and Tor2 as the targets of sirolimus and provided robust support that the FKBP12-sirolimus complex binds to and inhibits Tor1 and Tor2. Sirolimus
9877-437: The first enzyme-free product. The macrocyclic core is then customized by a series of post-PKS enzymes through methylations by MTases and oxidations by P-450s to yield rapamycin. The antiproliferative effects of sirolimus may have a role in treating cancer. When dosed appropriately, sirolimus can enhance the immune response to tumor targeting or otherwise promote tumor regression in clinical trials. Sirolimus seems to lower
9996-686: The first four modules of polyketide chain elongation are in RapA, the following six modules for continued elongation are in RapB, and the final four modules to complete the biosynthesis of the linear polyketide are in RapC. Then, the linear polyketide is modified by the NRPS, RapP, which attaches L-pipecolate to the terminal end of the polyketide, and then cyclizes the molecule, yielding the unbound product, prerapamycin. The core macrocycle , prerapamycin (figure 2),
10115-534: The first phase of T lymphocyte activation, sirolimus affects the second phase, namely signal transduction and lymphocyte clonal proliferation. It binds to FKBP1A like tacrolimus, however the complex does not inhibit calcineurin but another protein, mTOR . Therefore, sirolimus acts synergistically with ciclosporin and, in combination with other immunosuppressants, has few side effects. Also, it indirectly inhibits several T lymphocyte-specific kinases and phosphatases, hence preventing their transition from G 1 to S phase of
10234-413: The inhibition and the exact extent to which mTORC1 and mTORC2 are inhibited play a role, but were not yet well understood according to a 2015 paper. When applied as a topical preparation, researchers showed that rapamycin can regenerate collagen and reverse clinical signs of aging in elderly patients. The concentrations are far lower than those used to treat angiofibromas. Rapamycin has been proposed as
10353-399: The macrocyclic core to give rapamycin (figure 3). Finally, rapG and rapH have been identified to code for enzymes that have a positive regulatory role in the preparation of rapamycin through the control of rapamycin PKS gene expression. Biosynthesis of this 31-membered macrocycle begins as the loading domain is primed with the starter unit, 4,5-dihydroxocyclohex-1-ene-carboxylic acid, which
10472-485: The molecule from the module 10. The process of L -pipecolic acid synthesis is NRPS enforced by fkbP enzyme. After synthesizing the entire subunits, the molecule is cyclized. After the cyclization, the pre-tacrolimus molecule goes through the post-synthase tailoring steps such as oxidation and S -adenosyl methionine . Particularly fkbM enzyme is responsible of alcohol methylation targeting the alcohol of DHCHC starter unit (Carbon number 31 depicted in brown), and fkbD enzyme
10591-759: The name Protopic . [REDACTED] [REDACTED] [REDACTED] The biosynthesis of tacrolimus is hybrid synthesis of both type 1 polyketide synthases (PKS 1) and nonribosomal peptide syntheses (NRPS). The research shows the hybrid synthesis consists of ten modules of type 1 polyketide synthase and one module of nonribosomal peptide synthase. The synthetic enzymes for tacrolimus are found in 19 gene clusters named fkb. The 19 genes are fkbQ, fkbN, fkbM, fkbD, fkbA, fkbP, fkbO, fkbB, fkbC, fkbL, fkbK, fkbJ, fkbI, fkbH, fkbG, allD, allR, allK and allA. There are several possible ways of biosynthesis of tacrolimus. The fundamental units for biosynthesis are following: one molecule of 4,5-dihydroxycyclohex-1-enecarboxylic acid (DHCHC) as
10710-531: The nucleus of the T cell and increases the activity of genes coding for IL-2 and related cytokines. Tacrolimus prevents the dephosphorylation of NF-AT. In detail, tacrolimus reduces peptidylprolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein), creating a new complex. This FKBP12–FK506 complex interacts with and inhibits calcineurin, thus inhibiting both T lymphocyte signal transduction and IL-2 transcription. Although this activity
10829-451: The pharmacokinetics of tacrolimus. Tacrolimus was discovered in 1987; it was among the first macrolide immunosuppressants discovered, preceded by the discovery of rapamycin (sirolimus) on Rapa Nui (Easter Island) in 1975. It is produced by a soil bacterium, Streptomyces tsukubensis . The name tacrolimus is derived from " Tsukuba macrolide immunosuppressant". The early development (investigational new drug phase) of tacrolimus, called at
10948-465: The production of Th1 cytokines and the activation of monocytes. It is used to slow down the progression of multiple sclerosis . IFN-γ is able to trigger lymphocytic apoptosis . Prolonged use of opioids may cause immunosuppression of both innate and adaptive immunity. Decrease in proliferation as well as immune function has been observed in macrophages, as well as lymphocytes. It is thought that these effects are mediated by opioid receptors expressed on
11067-719: The proliferation of regulatory T cells, inhibiting cytotoxic T cells and lowering the differentiation of effector T cells. Rapamycin is used in biology research as an agent for chemically induced dimerization . In this application, rapamycin is added to cells expressing two fusion constructs, one of which contains the rapamycin-binding FRB domain from mTOR and the other of which contains an FKBP domain. Each fusion protein also contains additional domains that are brought into proximity when rapamycin induces binding of FRB and FKBP. In this way, rapamycin can be used to control and study protein localization and interactions. A number of veterinary medicine teaching hospitals are participating in
11186-455: The prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults and children. A branded version of the drug is owned by Astellas Pharma , and is sold under the brand name Prograf, given twice daily. A number of other manufacturers hold marketing authorisation for alternative brands of
11305-403: The rate of recurrence can be high and surgery can have complications. Sirolimus has shown evidence of being an effective treatment in alleviating symptoms and reducing the size of the malformation by way of altering the mTOR pathway in lymphangiogenesis. Although an off label use of the drug, Sirolimus has been shown to be an effective treatment for both microcystic and macrocystic LM. More research
11424-642: The release of various inflammatory mediators (lysosomal enzymes, cytokines, tissue plasminogen activator , chemokines , etc.) from neutrophils , macrophages , and mastocytes . Cytostatics inhibit cell division . In immunotherapy, they are used in smaller doses than in the treatment of malignant diseases. They affect the proliferation of both T cells and B cells. Due to their highest effectiveness, purine analogs are most frequently administered. The alkylating agents used in immunotherapy are nitrogen mustards ( cyclophosphamide ), nitrosoureas , platinum compounds, and others. Cyclophosphamide (Baxter's Cytoxan)
11543-461: The risk of contracting tuberculosis or inducing a latent infection to become active. Infliximab and adalimumab have label warnings stating that patients should be evaluated for latent TB infection and treatment should be initiated prior to starting therapy with them. TNF or the effects of TNF are also suppressed by various natural compounds, including curcumin (an ingredient in turmeric ) and catechins (in green tea ). Mycophenolic acid acts as
11662-404: The sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity. This compound also has a use in cardiovascular drug-eluting stent technologies to inhibit restenosis . It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of Streptomyces hygroscopicus found on Easter Island . The compound
11781-458: The severity of existing fungal or infectious conditions such as herpes zoster or polyoma viral infections. In people receiving immunosuppressants to reduce transplant graft rejection, an increased risk of malignancy (cancer) is a recognised complication. The most common cancers are non-Hodgkin's lymphoma and skin cancers . The risk appears to be related to the intensity and duration of treatment. The most common adverse events associated with
11900-443: The steroid-resistant acute rejection reaction and grave aplastic anemia treatment. However, they are added primarily to other immunosuppressives to diminish their dosage and toxicity. They also allow transition to cyclosporin therapy. Polyclonal antibodies inhibit T lymphocytes and cause their lysis , which is both complement -mediated cytolysis and cell-mediated opsonization followed by removal of reticuloendothelial cells from
12019-461: The subject of a number of ongoing clinical trials. In May 2015, the FDA approved sirolimus to treat lymphangioleiomyomatosis (LAM), a rare, progressive lung disease that primarily affects women of childbearing age. This made sirolimus the first drug approved to treat this disease. LAM involves lung tissue infiltration with smooth muscle -like cells with mutations of the tuberous sclerosis complex gene ( TSC2 ). Loss of TSC2 gene function activates
12138-794: The suppression of flares of UC. A 2022 updated Cochrane systematic review found that tacrolimus may be superior to placebo in achieving remission and improvement in UC. Immunosuppressive drug Immunosuppressive drugs , also known as immunosuppressive agents , immunosuppressants and antirejection medications , are drugs that inhibit or prevent the activity of the immune system . Immunosuppressive drugs can be classified into five groups: In pharmacologic (supraphysiologic) doses, glucocorticoids, such as prednisone , dexamethasone , and hydrocortisone are used to suppress various allergic , inflammatory , and autoimmune disorders. They are also administered as posttransplantory immunosuppressants to prevent
12257-504: The surface of these immune cells. A TNF-α (tumor necrosis factor-alpha) binding protein is a monoclonal antibody or a circulating receptor such as infliximab (Remicade), etanercept (Enbrel), or adalimumab (Humira) that binds to TNF-α, preventing it from inducing the synthesis of IL-1 and IL-6 and the adhesion of lymphocyte-activating molecules. They are used in the treatment of rheumatoid arthritis , ankylosing spondylitis , Crohn's disease , and psoriasis . These drugs may raise
12376-446: The system's metabolic activity. Interactions include that with grapefruit which increases tacrolimus plasma concentrations. As infections are a major cause of morbidity and mortality in the post-transplant patient, the most commonly reported interactions include interactions with anti-microbial drugs. Macrolide antibiotics including erythromycin and clarithromycin , as well as several of the newer classes of antifungals, especially of
12495-536: The time by the development code FK-506, happened in the next several years. A firsthand account of that process is given in Thomas Starzl 's 1992 memoir. Tacrolimus was first approved by the US Food and Drug Administration (FDA) in 1994, for use in liver transplantation ; the indications were extended to include kidney transplants. Generic versions of tacrolimus were approved in the US in 2017. Tacrolimus
12614-457: The tradename Cypher . However, this kind of stent may also increase the risk of vascular thrombosis. Sirolimus is used to treat vascular malformations. Treatment with sirolimus can decrease pain and the fullness of vascular malformations, improve coagulation levels, and slow the growth of abnormal lymphatic vessels. Sirolimus is a relatively new medical therapy for the treatment of vascular malformations in recent years, sirolimus has emerged as
12733-533: The transcription of interleukin-2 . The drug also inhibits lymphokine production and interleukin release, leading to a reduced function of effector T-cells. Ciclosporin is used in the treatment of acute rejection reactions, but has been increasingly substituted with newer, and less nephrotoxic , immunosuppressants. Calcineurin inhibitors and azathioprine have been linked with post-transplant malignancies and skin cancers in organ transplant recipients. Non-melanoma skin cancer (NMSC) after kidney transplantation
12852-451: The treatment of lymphangioleiomyomatosis are: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, chest pain, stomatitis , nasopharyngitis , acne, upper respiratory tract infection , dizziness, and myalgia . The following adverse effects occurred in 3–20% of individuals taking sirolimus for organ rejection prophylaxis following a kidney transplant: While sirolimus inhibition of mTORC1 appears to mediate
12971-426: The treatment. It is characterized by fever , rigor episodes, and even anaphylaxis . Later during the treatment, some patients develop serum sickness or immune complex glomerulonephritis . Serum sickness arises seven to fourteen days after the therapy has begun. The patient has fever, joint pain , and erythema that can be soothed with the use of steroids and analgesics . Urticaria (hives) can also be present. It
13090-464: The twice-daily formulation. Once-daily formulations with marketing authorisation include Advagraf (Astellas Pharma) and Envarsus (marketed as Envarsus XR in US by Veloxis Pharmaceuticals and marketed in Europe by Chiesi ). These formulations are intended to reduce pharmacokinetic variation in blood levels and facilitate compliance with dosing. The topical formulation is marketed by LEO Pharma under
13209-577: The use of sirolimus in transplants, where it may increase mortality due to an increased risk of infections. Sirolimus may increase an individual's risk for contracting skin cancers from exposure to sunlight or UV radiation, and risk of developing lymphoma . In studies, the skin cancer risk under sirolimus was lower than under other immunosuppressants such as azathioprine and calcineurin inhibitors , and lower than under placebo . Individuals taking sirolimus are at increased risk of experiencing impaired or delayed wound healing, particularly if they have
13328-540: The use of these new drugs. A 2023 systematic review and meta-analysis published in The Lancet Child & Adolescent Health concluded with moderate-certainty evidence that the two drugs were not associated with any increased risk of cancer. Also like cyclosporin, it has a wide range of interactions. Tacrolimus is primarily metabolised by the cytochrome P450 system of liver enzymes, and there are many substances that interact with this system and induce or inhibit
13447-408: The use of topical tacrolimus ointments, especially if used over a wide area, include a burning or itching sensation on the initial applications, with increased sensitivity to sunlight and heat on the affected areas. Less common are flu-like symptoms , headache, cough, and burning eyes. Tacrolimus and a related drug for eczema ( pimecrolimus ) were suspected of carrying a cancer risk, though the matter
13566-555: The year 1998: basiliximab (Simulect) and daclizumab (Zenapax). These drugs act by binding the IL-2a receptor's α chain, preventing the IL-2 induced clonal expansion of activated lymphocytes and shortening their survival. They are used in the prophylaxis of the acute organ rejection after bilateral kidney transplantation , both being similarly effective and with only few side-effects. Like tacrolimus , ciclosporin (Novartis' Sandimmune)
13685-684: Was approved by the FDA for treating angiofibromas. The most common adverse reactions (≥30% occurrence, leading to a 5% treatment discontinuation rate) observed with sirolimus in clinical studies of organ rejection prophylaxis in individuals with kidney transplants include: peripheral edema , hypercholesterolemia , abdominal pain, headache, nausea, diarrhea, pain, constipation, hypertriglyceridemia , hypertension , increased creatinine , fever, urinary tract infection , anemia , arthralgia , and thrombocytopenia . The most common adverse reactions (≥20% occurrence, leading to an 11% treatment discontinuation rate) observed with sirolimus in clinical studies for
13804-427: Was approved for medical use in the European Union in 2002, for the treatment of moderate to severe atopic dermatitis. In 2007, the indications were expanded to include the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults. In 2009, the indications were expanded to include
13923-588: Was concluded in 2016 that more research was required before sirolimus could be widely prescribed for this purpose. Two human studies on the effects of sirolimus (rapamycin) on longevity did not show statistically significant benefits. However, due to limitations in the studies, further research is needed to fully assess its potential in humans. Sirolimus has complex effects on the immune system—while IL-12 goes up and IL-10 decreases, which suggests an immunostimulatory response, TNF and IL-6 are decreased, which suggests an immunosuppressive response. The duration of
14042-405: Was considered for treatment of LAM, it received orphan drug designation status because LAM is a rare condition. The safety of LAM treatment by sirolimus in people younger than 18 years old has not been tested. The antiproliferative effect of sirolimus has also been used in conjunction with coronary stents to prevent restenosis in coronary arteries following balloon angioplasty. The sirolimus
14161-460: Was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR . It was approved by the U.S. Food and Drug Administration (FDA) in 1999. Hyftor (sirolimus gel) was approved for topical treatment of facial angiofibroma in
#364635